Search

Your search keyword '"Bristow RG"' showing total 6 results
Start Over Author "Bristow RG" Language undetermined
6 results on '"Bristow RG"'

3. Erratum: Corrigendum: Analysis of the genetic phylogeny of multifocal prostate cancer identifies multiple independent clonal expansions in neoplastic and morphologically normal prostate tissue

Author

Cooper, CS, Eeles, R, Wedge, DC, Van Loo, P, Gundem, G, Alexandrov, LB, Kremeyer, B, Butler, A, Lynch, AG, Camacho, N, Massie, CE, Kay, J, Luxton, HJ, Edwards, S, Kote-Jarai, Z, Dennis, N, Merson, S, Leongamornlert, D, Zamora, J, Corbishley, C, Thomas, S, Nik-Zainal, S, Ramakrishna, M, O'Meara, S, Matthews, L, Clark, J, Hurst, R, Mithen, R, Bristow, RG, Boutros, PC, Fraser, M, Cooke, S, Raine, K, Jones, D, Menzies, A, Stebbings, L, Hinton, J, Teague, J, McLaren, S, Mudie, L, Hardy, C, Anderson, E, Joseph, O, Goody, V, Robinson, B, Maddison, M, Gamble, S, Greenman, C, Berney, D, Hazell, S, Livni, N, ICGC Prostate Group, Fisher, C, Ogden, C, Kumar, P, Thompson, A, Woodhouse, C, Nicol, D, Mayer, E, Dudderidge, T, Shah, NC, Gnanapragasam, V, Voet, T, Campbell, P, Futreal, A, Easton, D, Warren, AY, Foster, CS, Stratton, MR, Whitaker, HC, McDermott, U, Brewer, DS, and Neal, DE

Subjects
Genetics, Prostate cancer, medicine.anatomical_structure, Phylogenetics, Prostate, ICGC Prostate Group, medicine, 11 Medical And Health Sciences, 06 Biological Sciences, Biology, medicine.disease, Developmental Biology
Published
2015

5. Excellent translational research in oncology: A journey towards novel and more effective anti-cancer therapies

Author

Rajan, A, Berns, A, Ringborg, U, Celis, J, Ponder, B, Caldas, C, Livingston, D, Bristow, RG, Hecht, TT, Tursz, T, Van Luenen, H, Bono, P, Helander, T, Seamon, K, Smyth, JF, Louvard, D, Eggermont, A, and Van Harten, WH

Subjects
Europe, Translational Research, Biomedical, Performance assessment, Neoplasms, Excellence, Humans, Quality improvement, Translational research, Cancer Care Facilities, 3. Good health, Quality of Health Care
Abstract

Comprehensive Cancer Centres (CCCs) serve as critical drivers for improving cancer survival. In Europe, we have developed an Excellence Designation System (EDS) consisting of criteria to assess "excellence" of CCCs in translational research (bench to bedside and back), with the expectation that many European CCCs will aspire to this status.

6. Management of Patients with Advanced Prostate Cancer: Report of the Advanced Prostate Cancer Consensus Conference 2019

Author

Charles G. Drake, Matthew R. Smith, Almudena Zapatero, Charles J. Ryan, Philip W. Kantoff, Piet Ost, Inge M. van Oort, Ian D. Davis, Nicolas James, Matthew R. Sydes, Vedang Murthy, Martin E. Gleave, Maha Hussain, Michael S Hofman, Susan Halabi, Ignacio Duran, Oliver Sartor, Raya Leibowitz, Christopher P. Evans, Anders Bjartell, Ros Eeles, Mack Roach, Hiroyoshi Suzuki, Colin C. Pritchard, Levent Türkeri, Daniel Heinrich, Fred Saad, William Oh, Karim Fizazi, Himisha Beltran, Declan G. Murphy, Joe M. O'Sullivan, Thomas Steuber, Raja B. Khauli, Axel Heidenreich, Silke Gillessen, Eric J. Small, Robert E. Reiter, Juan Pablo Sade, Chris Logothetis, Tomasz M. Beer, Alberto Briganti, Mary-Ellen Taplin, Johann S. de Bono, Howard I. Scher, Eleni Efstathiou, Stefano Fanti, Darren M.C. Poon, Felix Y. Feng, Aurelius Omlin, Hind Mrabti, Chris Parker, Anwar R. Padhani, Kim N. Chi, Mark A. Rubin, Neal D. Shore, Nicolas Mottet, Alicia K. Morgans, Christopher Sweeney, Mark Frydenberg, Robert G. Bristow, Fernando C. Maluf, Robin Millman, Cora N. Sternberg, Ravindran Kanesvaran, Michael J. Morris, Noel W. Clarke, Gerhardt Attard, Alberto Bossi, Bertrand Tombal, Celestia S. Higano, Howard R. Soule, Acibadem University Dspace, UCL - SSS/IREC/CHEX - Pôle de chirgurgie expérimentale et transplantation, UCL - (SLuc) Service d'urologie, and Gillessen S, Attard G, Beer TM, Beltran H, Bjartell A, Bossi A, Briganti A, Bristow RG, Chi KN, Clarke N, Davis ID, de Bono J, Drake CG, Duran I, Eeles R, Efstathiou E, Evans CP, Fanti S, Feng FY, Fizazi K, Frydenberg M, Gleave M, Halabi S, Heidenreich A, Heinrich D, Higano CTS, Hofman MS, Hussain M, James N, Kanesvaran R, Kantoff P, Khauli RB, Leibowitz R, Logothetis C, Maluf F, Millman R, Morgans AK, Morris MJ, Mottet N, Mrabti H, Murphy DG, Murthy V, Oh WK, Ost P, O'Sullivan JM, Padhani AR, Parker C, Poon DMC, Pritchard CC, Reiter RE, Roach M, Rubin M, Ryan CJ, Saad F, Sade JP, Sartor O, Scher HI, Shore N, Small E, Smith M, Soule H, Sternberg CN, Steuber T, Suzuki H, Sweeney C, Sydes MR, Taplin ME, Tombal B, Türkeri L, van Oort I, Zapatero A, Omlin A.

Subjects
Male, Oncology, Aging, Advanced prostate cance, Hormone-sensitive prostate cancer, Imaging, SALVAGE RADIATION-THERAPY, Prostate cancer, QUALITY-OF-LIFE, Medicine and Health Sciences, Overall survival, Neoplasm Metastasis, DISSECTION, Cancer, Castration-resistant prostate cancer, Tumour genomic profiling, Advanced prostate cancer, Prostate Cancer, RADICAL PROSTATECTOMY, Consensus conference, Progression-free survival, TESTOSTERONE MEASUREMENTS, Urology & Nephrology, High-risk localised prostate cancer, Prostate cancer treatment, Local, Practice Guidelines as Topic, PHASE-II, Overall, profiling, CLINICAL-TRIALS, Urologic Diseases, medicine.medical_specialty, Urology, Clinical Sciences, Bone Neoplasms, HOT FLASHES, survival, All institutes and research themes of the Radboud University Medical Center, Internal medicine, Urological cancers Radboud Institute for Molecular Life Sciences [Radboudumc 15], Castration-naïve prostate cancer, Genetics, medicine, Humans, LYMPH-NODE, Neoplasm Staging, business.industry, Tumour genomic, Prostatic Neoplasms, Prostate-Specific Antigen, medicine.disease, Oligometastatic prostate cancer, LYMPH-NODE DISSECTION, Hormone sensitive prostate cancer, Neoplasm Recurrence, Good Health and Well Being, ANDROGEN-DEPRIVATION THERAPY, Neoplasm Recurrence, Local, FREE SURVIVAL, business
Abstract

Background: Innovations in treatments, imaging, and molecular characterisation in advanced prostate cancer have improved outcomes, but there are still many aspects of management that lack high-level evidence to inform clinical practice. The Advanced Prostate Cancer Consensus Conference (APCCC) 2019 addressed some of these topics to supplement guidelines that are based on level 1 evidence. Objective: To present the results from the APCCC 2019. Design, setting, and participants: Similar to prior conferences, experts identified 10 important areas of controversy regarding the management of advanced prostate cancer: locally advanced disease, biochemical recurrence after local therapy, treating the primary tumour in the metastatic setting, metastatic hormone-sensitive/naive prostate cancer, nonmetastatic castration-resistant prostate cancer, metastatic castration-resistant prostate cancer, bone health and bone metastases, molecular characterisation of tissue and blood, inter- and intrapatient heterogeneity, and adverse effects of hormonal therapy and their management. A panel of 72 international prostate cancer experts developed the programme and the consensus questions. Outcome measurements and statistical analysis: The panel voted publicly but anonymously on 123 predefined questions, which were developed by both voting and nonvoting panel members prior to the conference following a modified Delphi process. Results and limitations: Panellists voted based on their opinions rather than a standard literature review or formal meta-analysis. The answer options for the consensus questions had varying degrees of support by the panel, as reflected in this article and the detailed voting results reported in the Supplementary material. Conclusions: These voting results from a panel of prostate cancer experts can help clinicians and patients navigate controversial areas of advanced prostate management for which high-level evidence is sparse. However, diagnostic and treatment decisions should always be individualised based on patient-specific factors, such as disease extent and location, prior lines of therapy, comorbidities, and treatment preferences, together with current and emerging clinical evidence and logistic and economic constraints. Clinical trial enrolment for men with advanced prostate cancer should be strongly encouraged. Importantly, APCCC 2019 once again identified important questions that merit assessment in specifically designed trials. Patient summary: The Advanced Prostate Cancer Consensus Conference provides a forum to discuss and debate current diagnostic and treatment options for patients with advanced prostate cancer. The conference, which has been held three times since 2015, aims to share the knowledge of world experts in prostate cancer management with health care providers worldwide. At the end of the conference, an expert panel discusses and votes on predefined consensus questions that target the most clinically relevant areas of advanced prostate cancer treatment. The results of the voting provide a practical guide to help clinicians discuss therapeutic options with patients as part of shared and multidisciplinary decision making. (C) 2020 The Authors. Published by Elsevier B.V. on behalf of European Association of Urology.

Published
2020

Catalog

Books, media, physical & digital resources
See catalog results